Sacubitril/Valsartan Versus Enalapril in Chronic Chagas Cardiomyopathy: Rationale and Design of the PARACHUTE-HF Trial.
JACC Heart Fail
; 12(8): 1473-1486, 2024 Aug.
Article
en En
| MEDLINE
| ID: mdl-39111953
ABSTRACT
Chronic Chagas cardiomyopathy (CCC) has unique pathogenic and clinical features with worse prognosis than other causes of heart failure (HF), despite the fact that patients with CCC are often younger and have fewer comorbidities. Patients with CCC were not adequately represented in any of the landmark HF studies that support current treatment guidelines. PARACHUTE-HF (Prevention And Reduction of Adverse outcomes in Chagasic Heart failUre Trial Evaluation) is an active-controlled, randomized, phase IV trial designed to evaluate the effect of sacubitril/valsartan 200 mg twice daily vs enalapril 10 mg twice daily added to standard of care treatment for HF. The study aims to enroll approximately 900 patients with CCC and reduced ejection fraction at around 100 sites in Latin America. The primary outcome is a hierarchical composite of time from randomization to cardiovascular death, first HF hospitalization, or relative change from baseline to week 12 in NT-proBNP levels. PARACHUTE-HF will provide new data on the treatment of this high-risk population. (Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With CCC [PARACHUTE-HF]; NCT04023227).
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Tetrazoles
/
Compuestos de Bifenilo
/
Enalapril
/
Cardiomiopatía Chagásica
/
Combinación de Medicamentos
/
Antagonistas de Receptores de Angiotensina
/
Valsartán
/
Aminobutiratos
/
Insuficiencia Cardíaca
Límite:
Female
/
Humans
/
Male
Idioma:
En
Año:
2024
Tipo del documento:
Article